For Germany, the current status is: Mysimba is currently not on the market
If its been too long, just skip and do the next scheduled dose
I look forward to seeing how adoption develops, how the competitive landscape (other GLP-1/dual therapies) responds, and how this influences commercial models for obesity/diabetes therapies in India
People switching between different GLP-1 medications, such as those switching from semaglutide to tirzepatide , should know that side effect profiles differ between these drugs even though they target similar pathways
Additionally, you should focus on staying hydrated and eating smaller, more frequent meals
Jaisinghani says everyone responds to these medications differently, losing body mass at different rates